Free Trial
NASDAQ:IRTC

iRhythm Technologies (IRTC) Stock Price, News & Analysis

iRhythm Technologies logo
$119.58 +6.91 (+6.13%)
Closing price 02/21/2025 03:59 PM Eastern
Extended Trading
$121.25 +1.67 (+1.39%)
As of 02/21/2025 07:13 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About iRhythm Technologies Stock (NASDAQ:IRTC)

Key Stats

Today's Range
$116.25
$128.52
50-Day Range
$85.95
$119.58
52-Week Range
$55.92
$128.52
Volume
1.78 million shs
Average Volume
344,914 shs
Market Capitalization
$3.74 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$115.55
Consensus Rating
Moderate Buy

Company Overview

iRhythm Technologies, Inc., a digital healthcare company, engages in the design, development, and commercialization of device-based technology to provide ambulatory cardiac monitoring services to diagnose arrhythmias in the United States. It offers Zio services, an ambulatory monitoring solution, including long-term and short-term continuous monitoring and mobile cardiac telemetry monitoring services. The company also provides the Zio Monitor System, a prescription-only, remote electrocardiogram (ECG) monitoring system that consists of a patch ECG monitor that records the electric signal from the heart continuously for up to 14 days and the Zio ECG Utilization Software System, which supports the capture and analysis of ECG data recorded by the Zio Monitor patch at the end of the wear period, including specific arrhythmia events detected by the ZEUS System; the Zio XT System is the previous generation of the Zio Monitor System and is a prescription-only, remote ECG monitoring system that consists of the Zio XT patch that records the electric signal from the heart continuously for up to 14 days; and the Zio AT system, a prescription-only, remote ECG monitoring system that similarly consists of the Zio AT patch that records the electric signal from the heart continuously for up to 14 days and the ZEUS System, but which also incorporates the Zio AT wireless gateway that provides connectivity between the Zio AT patch and the ZEUS System during the patient wear period. It has a development collaboration agreement with Verily Life Sciences LLC and Verity Ireland Limited to develop various next-generation atrial fibrillation screening, detection, or monitoring products. The company was incorporated in 2006 and is headquartered in San Francisco, California.

iRhythm Technologies Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
23rd Percentile Overall Score

IRTC MarketRank™: 

iRhythm Technologies scored higher than 23% of companies evaluated by MarketBeat, and ranked 867th out of 950 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    iRhythm Technologies has received a consensus rating of Moderate Buy. The company's average rating score is 2.82, and is based on 9 buy ratings, 2 hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    iRhythm Technologies has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

  • Read more about iRhythm Technologies' stock forecast and price target.
  • Earnings Growth

    Earnings for iRhythm Technologies are expected to grow in the coming year, from ($1.98) to ($1.03) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of iRhythm Technologies is -32.85, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of iRhythm Technologies is -32.85, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    iRhythm Technologies has a P/B Ratio of 17.46. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

  • Read more about iRhythm Technologies' valuation and earnings.
  • Percentage of Shares Shorted

    7.73% of the outstanding shares of iRhythm Technologies have been sold short.
  • Short Interest Ratio / Days to Cover

    iRhythm Technologies has a short interest ratio ("days to cover") of 6.3.
  • Change versus previous month

    Short interest in iRhythm Technologies has recently increased by 3.86%, indicating that investor sentiment is decreasing.
  • Dividend Yield

    iRhythm Technologies does not currently pay a dividend.

  • Dividend Growth

    iRhythm Technologies does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    7.73% of the outstanding shares of iRhythm Technologies have been sold short.
  • Short Interest Ratio / Days to Cover

    iRhythm Technologies has a short interest ratio ("days to cover") of 6.3.
  • Change versus previous month

    Short interest in iRhythm Technologies has recently increased by 3.86%, indicating that investor sentiment is decreasing.
  • News Sentiment

    iRhythm Technologies has a news sentiment score of 0.73. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.60 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 19 news articles for iRhythm Technologies this week, compared to 6 articles on an average week.
  • Search Interest

    Only 1 people have searched for IRTC on MarketBeat in the last 30 days. This is a decrease of -92% compared to the previous 30 days.
  • MarketBeat Follows

    Only 1 people have added iRhythm Technologies to their MarketBeat watchlist in the last 30 days. This is a decrease of -94% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, iRhythm Technologies insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $214,038.00 in company stock.

  • Percentage Held by Insiders

    Only 0.68% of the stock of iRhythm Technologies is held by insiders.

  • Read more about iRhythm Technologies' insider trading history.
Receive IRTC Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for iRhythm Technologies and its competitors with MarketBeat's FREE daily newsletter.

IRTC Stock News Headlines

Watch This Robotics Demo Before March 17th
Jeff Brown, the tech legend who picked shares of Nvidia in 2016 before they jumped by more than 22,000%... Just did a demo of what Nvidia’s CEO said will be "the first multitrillion-dollar robotics industry."
iRhythm stock rises on strong Q4 results and outlook
BTIG Sticks to Their Buy Rating for Irhythm Technologies (IRTC)
See More Headlines

IRTC Stock Analysis - Frequently Asked Questions

iRhythm Technologies' stock was trading at $90.17 at the start of the year. Since then, IRTC stock has increased by 32.6% and is now trading at $119.5820.
View the best growth stocks for 2025 here
.

iRhythm Technologies, Inc. (NASDAQ:IRTC) issued its quarterly earnings results on Thursday, February, 20th. The company reported $0.01 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.29) by $0.30. The company earned $164.33 million during the quarter, compared to the consensus estimate of $158.30 million. iRhythm Technologies had a negative trailing twelve-month return on equity of 118.83% and a negative net margin of 19.14%.

iRhythm Technologies (IRTC) raised $76 million in an initial public offering on Thursday, October 20th 2016. The company issued 5,400,000 shares at a price of $13.00-$15.00 per share. J.P. Morgan and Morgan Stanley acted as the underwriters for the IPO and Canaccord Genuity and BTIG were co-managers.

iRhythm Technologies' top institutional shareholders include Vanguard Group Inc. (10.02%), Artisan Partners Limited Partnership (8.83%), Capital Research Global Investors (5.23%) and Mackenzie Financial Corp (4.42%). Insiders that own company stock include Quentin S Blackford, Mark J Day, Chad Patterson, Patrick Michael Murphy, Daniel G Wilson, Douglas Devine, Minang Turakhia, Brice Bobzien, Sumi Shrishrimal, Abhijit Y Talwalkar, Mervin Smith, Marc W Rosenbaum, Merz Cathleen Noel Bairey, David A Vort and Kevin M King.
View institutional ownership trends
.

Shares of IRTC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that iRhythm Technologies investors own include NVIDIA (NVDA), Meta Platforms (META), Broadcom (AVGO), Adobe (ADBE), Advanced Micro Devices (AMD), Arista Networks (ANET) and ServiceNow (NOW).

Company Calendar

Last Earnings
2/20/2025
Today
2/22/2025
Next Earnings (Estimated)
5/01/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Sector
Medical
Industry
Surgical & medical instruments
Sub-Industry
Medical Equipment
Current Symbol
NASDAQ:IRTC
Fax
N/A
Employees
2,000
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$115.55
High Stock Price Target
$152.00
Low Stock Price Target
$78.00
Potential Upside/Downside
-3.4%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.82
Research Coverage
11 Analysts

Profitability

Net Income
$-123,410,000.00
Pretax Margin
-26.78%

Debt

Sales & Book Value

Annual Sales
$492.68 million
Book Value
$6.85 per share

Miscellaneous

Free Float
31,085,000
Market Cap
$3.74 billion
Optionable
Optionable
Beta
1.29
The Best High-Yield Dividend Stocks for 2025 Cover

Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.

Get This Free Report

This page (NASDAQ:IRTC) was last updated on 2/22/2025 by MarketBeat.com Staff
From Our Partners